19
Anti-obesity Medication Summary
(All have contraindications for hypersensitivity and pregnancy)
Drug
Description Main Side Effects
Metreleptin Subcutaneous Injection (Myalept
®
)
• Leptin analog
• Adjunct to diet as replacement therapy
to treat the complications of leptin
def iciency in patients with congenital or
acquired generalized lipodystrophy.
• Safety and effectiveness of metreleptin
for partial lipodystrophy not established.
• Not indicated for patients with
nonalcoholic steatohepatitis (NASH) or
HIV-related lipodystrophy.
• Not a DEA scheduled drug
• Headache
• Hypoglycemia
• Decreased weight
• Abdominal pain
Dosing
• Body weight 40 kg or less:
▶ Starting dose 0.06 mg/kg/day, increase or decrease by 0.02 mg/kg
to a maximum daily dose of 0.13 mg/kg.
• Males greater than 40 kg body weight:
▶ Starting dose 2.5 mg/day, increase or decrease by 1.25 mg to 2.5
mg/day to a maximum dose of 10 mg/day.
• Females greater than 40 kg body weight:
▶ Starting dose 5 mg/day, increase or decrease by 1.25 mg to 2.5 mg/
day to a maximum dose of 10 mg/day.
Warnings and precautions
• T-cell lymphoma
▶ Carefully consider benef its and risks of treatment with
metreleptin in patients with signif icant hematologic
abnormalities and/or acquired generalized lipodystrophy.
• Hypoglycemia
▶ A dose adjustment, including possible large reductions, of insulin
or insulin secretagogue may be necessary. Closely monitor
blood glucose in patients on concomitant insulin or insulin
secretagogue therapy.
• Autoimmunity
▶ Autoimmune disorder progression has been observed in patients
treated with metreleptin. Carefully consider benef its and risks of
metreleptin treatment in patients with autoimmune disease.
• Hypersensitivity
▶ Hypersensitivity reactions (e.g., urticaria or generalized rash) have
been reported. Patient should promptly seek medical advice
regarding suspected reactions.
(cont'd)
